News Lundbeck retreats from dozens of markets, slashing staff Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partners.
News Perlmutter's Eikon follows the IPO trail Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.